Eli Lilly Says FDA Approved Jaypirca for Adult Patients With Previously Untreated CLL/SLL

The FDA approved Eli Lilly's (LLY) Jaypirca as a first-line therapy for CLL/SLL. Clinical trials showed superior efficacy. LLY's stock is modestly undervalued according to GF Value™, with a GF Score™ of 96. Insiders sold $3.09B in shares over the past year. LLY's market cap is $1.08T.

The FDA approved Eli Lilly's Jaypirca (pirtobrutinib) as a first-line treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletion. This expands the drug's approved uses, according to the company.

Eli Lilly (LLY) received FDA approval for Jaypirca as a first-line treatment for CLL/SLL. The company's stock is deemed modestly undervalued with a GF Value of $1,563.25 vs. current price of $1,146.65. LLY has a GF Score of 96, indicating strong financial health and growth prospects. Insiders sold $3.09 billion in shares over the past year, while guru activity remains positive.

Eli Lilly (LLY) announced FDA approval of Jaypirca (pirtobrutinib) for first-line treatment of CLL/SLL in adults without 17p deletion. Approval based on BRUIN CLL-313 trial showing improved progression-free survival vs. bendamustine plus rituximab. CLL affects ~25% of new leukemia cases in the U.S.

Eli Lilly's Jaypirca (pirtobrutinib) received FDA approval for treating certain previously untreated CLL/SLL patients. The approval is based on BRUIN CLL-313 trial data showing significant disease progression delay. Jaypirca is the first-and-only approved non-covalent BTK inhibitor. The company reported key trial results, including a 94% overall response rate.

Eli Lilly (LLY) announced FDA approval for Jaypirca to treat certain untreated CLL/SLL patients. This expands the drug's indication, potentially boosting its uptake in Lilly's oncology portfolio. The company expects this to be a significant regulatory milestone.